Zheng-Rong Lian, Hai-Bo You, Xin Chen, Chuan-Xin Wu, Zuo-Jin Liu, Bing Tu, Jian-Ping Gong, Sheng-Wei Li
Department of Hepatobiliary Surgery, The Second Affiliated Hospital of Chongqing Medical University, Chongqing, China.
Am Surg. 2011 May;77(5):627-33.
The purpose of this study is to provide appropriate approaches for resection and drainage of hilar cholangiocarcinomas. Surgical approaches and postoperative survival rates of the patients were analyzed retrospectively. The 1-, 3-, and 5-year cumulative survival rates for patients who underwent resection were 76.6, 36.2, and 10.6 per cent, which was higher than those of 60, 14.3, and 0 per cent, respectively, in palliative operation. Moreover, the 1-, 3-, and 5-year cumulative survival rates for patients who underwent R0 were 88.9, 44.4, and 13.9 per cent, which was improved compared with those of 36.4, 9.1, and 0 per cent, respectively, in nonR0 resection. In addition, the overall survival time of patients who underwent R0 resection combined with hemihepatectomy and caudate lobe resection was longer than of those who underwent R0 without this extra operation, especially within 3 years after operation. After endoscopic metal biliary endoprothesis for patients who were intolerant of resection, liver function was improved at 2 weeks postoperation and the 1-, 3-, and 5-year cumulative survival rates for these patients were 72.7, 18.2, and 0 per cent, respectively. Treatment should be personalized. Resection is the most efficacious therapy, and negative histologic margins should be achieved in radical operation and "skeletonized" surgical operation is the basic requirement of radical treatment of hilar cholangiocarcinoma. Portal vein resection is beneficial to long-term survival and R0 resection combined with caudate lobe resection and hemihepatectomy is more efficacious for patients with Bismuth-Corlette type III hilar cholangiocarcinoma. The preferred approach of drainage in palliative operation is endoscopic metal biliary endoprothesis, which is more appropriate than tumor resection for the patients who suffer from serious comorbidities.
本研究的目的是为肝门部胆管癌的切除及引流提供合适的方法。对患者的手术方式及术后生存率进行回顾性分析。接受切除术患者的1年、3年和5年累积生存率分别为76.6%、36.2%和10.6%,高于姑息手术患者分别为60%、14.3%和0%的生存率。此外,接受R0切除患者的1年、3年和5年累积生存率分别为88.9%、44.4%和13.9%,与非R0切除患者分别为36.4%、9.1%和0%相比有所提高。另外,接受R0切除联合半肝切除及尾状叶切除患者的总生存时间长于未进行此额外手术的R0切除患者,尤其是术后3年内。对于不耐受切除的患者,在内镜金属胆道内支架置入术后,术后2周肝功能得到改善,这些患者的1年、3年和5年累积生存率分别为72.7%、18.2%和0%。治疗应个体化。切除是最有效的治疗方法,根治性手术应达到阴性切缘,“骨骼化”手术是肝门部胆管癌根治性治疗的基本要求。门静脉切除有利于长期生存,R0切除联合尾状叶切除及半肝切除对Bismuth-Corlette III型肝门部胆管癌患者更有效。姑息手术中首选的引流方法是内镜金属胆道内支架置入术,对于合并严重疾病的患者,该方法比肿瘤切除更合适。